Sort   by:  
 Page size 
GenomicClinical Crenolanib Resistance in AML

FLT3 mutations are commonly detected in Acute Myeloid Leukemia (AML) patients and are associated with poor prognosis. Crenolanib, a potent type I pan-FLT3 (GeneID:2322) inhibitor, is effective against both internal tandem ...

phs001628 | dbGaP
GenomicsClinical Resistance to Crenolanib in Acute Myeloid Leukemia Due to Diverse Molecular Mechanisms
Clinical Resistance to Crenolanib in Acute Myeloid Leukemia Due to Diverse Molecular Mechanisms
PRJNA476390 | ENA
GenomicsClinical Resistance to Crenolanib in Acute Myeloid Leukemia Due to Diverse Molecular Mechanisms
Clinical Resistance to Crenolanib in Acute Myeloid Leukemia Due to Diverse Molecular Mechanisms
PRJNA476391 | ENA
UnknownImproved Recovery from Liver Fibrosis by Crenolanib.
Not available
S-EPMC8067177 | biostudies-literature
UnknownCrenolanib is a selective type I pan-FLT3 inhibitor.
Not available
S-EPMC3986131 | biostudies-literature
ProteomicsTranslatome proteomics of primary human FLT3-ITD+ AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
Primary human AML cells (newly diagnosed, prior to treatment initation) was obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. Cells were treated ex vivo with DMSO vehicle control or 10 nM FLT3 inhibitors quizartinib, crenolanib, gilteritinib for 6 hour...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD034081 | Pride
Aml Gilteritinib Flt3 Translatome Quizartinib Crenolanib 
UnknownClinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
Not available
S-EPMC6335421 | biostudies-literature
TranscriptomicsCrenolanib in combination with azacitidine abrogates stromal protection and survival of leukemia-initiating cells in FLT3-ITD+ AML
Effectively targeting leukemia-initiating cells (LIC) in FLT3-internal-tandem-duplication (ITD)-mutated acute myeloid leukemia (AML) remains a crucial goal for achievement of cure. FLT3 tyrosine kinase inhibitors (TKI) have limited impact as single agents and have thus far been unable to eradicate L...
ORGANISM(S): Homo sapiens Mus musculus 
2017-04-03 | GSE86021 | GEO
GenomicsCrenolanib in combination with azacitidine abrogates stromal protection and survival of leukemia-initiating cells in FLT3-ITD+ AML
Crenolanib in combination with azacitidine abrogates stromal protection and survival of leukemia-initiating cells in FLT3-ITD+ AML
PRJNA339999 | ENA
UnknownPopulation pharmacokinetics of crenolanib in children and young adults with brain tumors.
Not available
S-EPMC8957602 | biostudies-literature
Sort   by:  
 Page size